Predicting Prognosis in CPEO With mtDNA Deletions: A Case Demonstrating the Advantages of Measuring Heteroplasmy With Novel Droplet Digital Polymerase Chain Reaction Testing
1 Department of Neurology and Ophthalmology (NL-C, ST, RCS, HTC, DK), Michigan State University, East Lansing, Michigan; Department of Neurology, Banner Neuroscience Institute (OS), University of Arizona, Phoenix, Arizona; Department of Ophthalmology (MF), Beaumont Hospital, Taylor, Michigan; Department of Pathology (HTC), Sparrow Health System, Lansing, Michigan; and Department of Laboratory Medicine and Pathology (ES, NV-F, and LH), Genomics Laboratory, Mayo Clinic, Rochester, Minnesota.